?Transgenic Gene Knockout Shared Resource Genetically modified mice are invaluable for SJCCC researchers to evaluate gene function in vivo and determine how specific genes regulate cell growth and differentiation in normal and tumor tissue. The Transgenic Gene Knockout Shared Resource (TGKSR) centralizes services for the generation of genetically modified mice and provides education, expertise, and cost effectiveness that would be extremely difficult to maintain in individual laboratories. The TGKSR Director is Hartmut Berns, PhD, an expert in transgenic technology with 23 years' experience creating genetically engineered mice, 16 years thereof in the management of transgenic cores at Comprehensive Cancer Centers. He is supported by 5 full-time technologists who employ state-of-the-art gene- modification technologies to produce transgenic mice by pronucleus injection of DNA into zygotes, ESC-based gene-targeted mice by injection of genetically engineered ESCs into blastocyst-staged embryos, and gene- edited mice. Engineered mice are also generated by injection of the endonucleases TALEN or CRISPR/Cas9 into the pronucleus or cytoplasm of zygotes to produce gene KOs, knock-ins (KIs), conditional genes, or point mutations. There has been marked impact of the TGKSR on the science of SJCCC members. Researchers have gained insights from germline-transmitting chimeras of 41 different ESC-based targeted genes, and multiple founders of 34 DNA constructs during the current funding cycle. The TGKSR was used by 18 investigators of whom 83% (n=15/18) are members of the Cancer Center. Of these, 93% (n=14/15) hold cancer- focused peer-reviewed grants. These SJCCC members were drawn from 4 of 5 SJCCC Programs and yielded a combined total of 57 publications from CBP (n=26), NBTP (n=22), HMP (n=13), and DBSTP (n=1). During the upcoming cycle, in recognition of the growing impact of CRISPR/Cas9 reagents on advancing research performed by the SJCCC, the TGKSR will further enhance interactions with the new Center for Advanced Genome Engineering (CAGE) Shared Resource. We will create standardized workflows for bringing reagents designed by CAGE into the TGKSR and, in turn, for validating GEM tissue samples by CAGE in order to optimize GEM production. We will carry out pilot projects to test reagent modifications and concentrations to identify the most efficient and effective CRISPR approaches by comparing the efficiencies of pronuclear injections and cytoplasmic injections in zygotes. Our goal is to optimize these new reagents and their application in zygotes (to generate KOs, small KIs, point mutations, conditional alleles) and in ESCs (to generate large KIs and more involved conditional and inducible alleles) to most efficiently provide GEM to SJCCC members. Additionally, microinjection, surgery, and animal rooms of the TGKSR are slated to move to a new vivarium to be constructed on the St. Jude campus, with ground-breaking slated for spring 2018 and opening for 2021. Thorough planning of the scope and size of microinjection capabilities and animal space has been initiated to ensure that the future needs of SJCCC members for GEM production are met.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA021765-40
Application #
9632012
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2019-03-01
Budget End
2020-02-29
Support Year
40
Fiscal Year
2019
Total Cost
Indirect Cost
Name
St. Jude Children's Research Hospital
Department
Type
DUNS #
067717892
City
Memphis
State
TN
Country
United States
Zip Code
38105
Hatfield, M Jason; Binder, Randall J; Gannon, Rowan et al. (2018) Potent, Irreversible Inhibition of Human Carboxylesterases by Tanshinone Anhydrides Isolated from Salvia miltiorrhiza (""Danshen""). J Nat Prod 81:2410-2418
Vo, BaoHan T; Kwon, Jin Ah; Li, Chunliang et al. (2018) Mouse medulloblastoma driven by CRISPR activation of cellular Myc. Sci Rep 8:8733
Shadrick, William R; Slavish, Peter J; Chai, Sergio C et al. (2018) Exploiting a water network to achieve enthalpy-driven, bromodomain-selective BET inhibitors. Bioorg Med Chem 26:25-36
Ramsey, Laura B; Balis, Frank M; O'Brien, Maureen M et al. (2018) Consensus Guideline for Use of Glucarpidase in Patients with High-Dose Methotrexate Induced Acute Kidney Injury and Delayed Methotrexate Clearance. Oncologist 23:52-61
Churchman, Michelle L; Qian, Maoxiang; Te Kronnie, Geertruy et al. (2018) Germline Genetic IKZF1 Variation and Predisposition to Childhood Acute Lymphoblastic Leukemia. Cancer Cell 33:937-948.e8
Huang, I-Chan; Brinkman, Tara M; Mullins, Larry et al. (2018) Child symptoms, parent behaviors, and family strain in long-term survivors of childhood acute lymphoblastic leukemia. Psychooncology 27:2031-2038
Huang, I-Chan; Klosky, James L; Young, Chelsea M et al. (2018) Misclassification of self-reported smoking in adult survivors of childhood cancer. Pediatr Blood Cancer 65:e27240
Mandrell, Belinda N; Avent, Yvonne; Walker, Breya et al. (2018) In-home salivary melatonin collection: Methodology for children and adolescents. Dev Psychobiol 60:118-122
Drummond, Catherine J; Hanna, Jason A; Garcia, Matthew R et al. (2018) Hedgehog Pathway Drives Fusion-Negative Rhabdomyosarcoma Initiated From Non-myogenic Endothelial Progenitors. Cancer Cell 33:108-124.e5
Jones, Conor M; Baker, Justin N; Keesey, Rachel M et al. (2018) Importance ratings on patient-reported outcome items for survivorship care: comparison between pediatric cancer survivors, parents, and clinicians. Qual Life Res 27:1877-1884

Showing the most recent 10 out of 6764 publications